Correo Electrónico
DNINFOA - SIA
Bibliotecas
Convocatorias
Identidad U.N.
Publicado
Absence of RET/PTC1 rearrangement in a sample of Colombian individuals with papillary thyroid carcinoma
Ausencia del rearreglo RET/PTC1 en una muestra de sujetos colombianos con carcinoma papilar de tiroides
Palabras clave:
Papillary Thyroid Carcinoma, Thyroiditis, Gene Rearrangement (en)Carcinoma papilar, Tiroiditis, Reordenamiento génico (es)
Descargas
Introduction: Papillary thyroid carcinoma is the most common endocrine neoplasm; therefore, markers with possible prognostic utility have been evaluated.
Objective: To analyze the presence of RET/PTC1 rearrangement, lymphocytic thyroiditis and associated clinical features in patients with papillary thyroid cancer treated at the Hospital de San José in Bogotá, Colombia.
Materials and methods: Clinical records of patients with complete thyroidectomy and diagnosis of papillary cancer were retrospectively identified. RNA was extracted from tumor tissue, and cDNA was obtained using inverse transcriptase to detect the rearrangement of the RET/PTC1 gene by means of qPCR.
Results: 55 patients with papillary thyroid cancer were selected; 93% were females, and the mean age was 45.8 years. The most frequent histological variant was classic (49%). A relationship was found between lymphocytic thyroiditis and the number of positive nodes in segments other than central draining, as well as thyroiditis and antithyroid antibody value. No RET/PTC1 rearrangement expression was found.
Conclusions: A relationship between lymphocytic thyroiditis and the number of positive nodes in segments other than central draining was found. Other molecular markers should be searched to differentiate the prognosis of these patients.
Introducción. El carcinoma papilar de tiroides es la neoplasia endocrina más común, por lo que se han evaluado marcadores con posible utilidad pronóstica.
Objetivo. Analizar la presencia del rearreglo del RET/PTC1, tiroiditis linfocítica y características clínicas asociadas en pacientes con cáncer papilar de tiroides en el Hospital de San José de Bogotá D.C., Colombia.
Materiales y métodos. Los casos con diagnóstico de cáncer papilar y tiroidectomía completa fueron seleccionados utilizando el registro de historias clínicas; el ARN se extrajo a partir del tejido tumoral y el ADNc se obtuvo utilizando una transcriptasa inversa para luego detectar el rearreglo del gen RET/PTC1 por medio de qPCR.
Resultados. Se seleccionaron 55 pacientes con cáncer papilar de tiroides; 93% correspondió a género femenino, la edad promedio fue de 45.8 años y la variante histológica más frecuente fue la clásica (49%). Se evidenció una relación entre tiroiditis linfocítica y la cantidad de ganglios positivos en segmentos distintos al vaciamiento central, así como la tiroiditis y el valor de los anticuerpos antitiroideos. No se identificó la expresión del rearreglo RET/PTC1 en las muestras analizadas.
Conclusiones. Se muestra una relación entre tiroiditis linfocítica y la cantidad de ganglios positivos en segmentos distintos al vaciamiento central. Se debe continuar la búsqueda de otros marcadores moleculares que permitan diferenciar el pronóstico en estos pacientes.
Descargas
Citas
Castro-Jiménez MÁ, López-Daza DF. Stability of mortality from thyroid cancer in a developing country. Rev. salud pública. 2015;17(1):1-1. http://doi.org/c4s6.
Vargas-Uricoechea H, Herrera-Chaparro J, Meza-Cabrera I, Agredo-Delgado V. Epidemiología del Cáncer de Tiroides. Revista Medicina. 2015;37(2):140-63.
Pelizzo MR, Merante-Boschin I, Toniato A, Pagetta C, Casal Ide E, Mian C, et al. Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma. Minerva Endocrinol. 2008;33(4):359-79.
Ozgursoy OB, Eisele DW, Tufano RP. The prognostic implications from molecular testing of thyroid cancer. Otolaryngol Clin North Am. 2014;47(4):595-607. http://doi.org/f6c732.
Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. Cancer. 1997;79(3):564-73.
McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley JD, Fein HG, et al. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid. 2014;24(1):35-42. http://doi.org/f5nv8h.
Soares P, Celestino R, Melo M, Fonseca E, Sobrinho-Simões M. Prognostic biomarkers in thyroid cancer. Virchows Arch. 2014;464(3):333-46. http://doi.org/f5vfm2.
Thomas GA, Bunnell H, Cook HA, Williams ED, Nerovnya A, Cherstvoy ED, et al. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab. 1999;84(11):4232-8. http://doi.org/c4s8.
Zou M, Shi Y, Farid NR. Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from Saudi Arabia. Cancer. 1994;73(1):176-80. http://doi.org/brgj7f.
Sugg SL, Ezzat S, Zheng L, Freeman JL, Rosen IB, Asa SL. Oncogene profile of papillary thyroid carcinoma. Surgery. 1999;125(1):46-52. http://doi.org/cmrhz7.
Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res. 1998;4(2):287-94.
Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol. 2016;12(4):192-202. http://doi.org/f8f8dp.
Prescott JD, Zeiger MA. The RET oncogene in papillary thyroid carcinoma. Cancer. 2015;121(13):2137-46. http://doi.org/c4s9.
Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30(2):216-22. http://doi.org/chk594.
Soares P, Fonseca E, Wynford-Thomas D, Sobrinho-Simões M. Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? J Pathol. 1998;185(1):71-8. http://doi.org/c589g7.
Puxeddu E, Moretti S, Giannico A, Martinelli M, Marino C, Avenia N, et al. Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. Eur J Endocrinol. 2003;148(5):505-13. http://doi.org/bm4c7k.
Dvorkin S, Robenshtok E, Hirsch D, Strenov Y, Shimon I, Benbassat CA. Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimotos thyroiditis. J Clin Endocrinol Metab. 2013;98(6):2409-14. http://doi.org/f4zt8t.
Guzmán GE, Sánchez-de Guzmán G, Tovar JR. Relación entre la presencia de tiroiditis linfocítica con la gravedad y recurrencia/persistencia del carcinoma diferenciado de tiroides. Rev. argent. endocrinol. metab. 2014;51(4):169-77.
Sheils OM, O’Leary JJ, Uhlmann V, Lüttich K, Sweeney EC. ret/PTC-1 activation in Hashimoto thyroiditis. Int J Surg Pathol. 2000;8(3):185-9. http://doi.org/bspnrx.
Asociación Médica Mundial. Declaración de Helsinki de la Asociación Médica Mundial. Principios éticos para las investigaciones médicas en seres humanos. Fortaleza: 64.a Asamblea General de la AMM; 2013.
Colombia. Ministerio de salud. Resolución 8430 de 1993 (octubre 4): Por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud. Bogotá D.C.; octubre 4 de 1993.
Rao PJ, Vardhini NV, Parvathi MV, Murthy PB, Sudhakar G. Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters. Tumour Biol. 2014;35(10):9539-48. http://doi.org/f6n97s.
Su X, Li Z, He C, Chen W, Fu X, Yang A. Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: a meta-analysis. Oncotarget. 2016;7(13):16716. http://doi.org/c4tb.
Sánchez G, Gutiérrez C, Valenzuela Á, Tovar JR. Carcinoma diferenciado de la glándula tiroidea: hallazgos en 16 años de manejo multidisciplinario. Rev Colomb Cir. 2014;29(2):102-9.
Pyzik A, Grywalska E, Matyjaszek-Matuszek B, Roliński J. Immune disorders in Hashimoto’s thyroiditis: what do we know so far? J Immunol Res. 2015;2015:979167. http://doi.org/gb5npt.
Ringel MD, Nabhan F. Approach to follow-up of the patient with differentiated thyroid cancer and positive anti-thyroglobulin antibodies. J Clin Endocrinol Metab. 2013;98(8):3104-10. http://doi.org/f46h9c.
Park JY, Kim DW, Park HK, Ha TK, Jung SJ, Kim DH, et al. Comparison of T stage, N stage, multifocality, and bilaterality in papillary thyroid carcinoma patients according to the presence of coexisting lymphocytic thyroiditis. Endocr Res. 2015;40(3):151-5. http://doi.org/c4tc.
Girardi FM, Barra MB, Zettler CG. Papillary thyroid carcinoma: does the association with Hashimoto’s thyroiditis affect the clinicopathological characteristics of the disease? Braz J Otorhinolaryngol. 2015;81(3):283-7. http://doi.org/f2v8hp.
Liu RT, Chou FF, Wang CH, Lin CL, Chao FP, Chung JC, et al. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese. Thyroid. 2005;15(4):326-35. http://doi.org/c83fpq.
El-Abdallah AA, Junaid TA. Overexpression of wild-type c-RET and zero prevalence of RET/PTC rearrangements are associated with papillary thyroid cancer (PTC) in Kuwait. Exp Mol Pathol. 2011;90(1):61-5. http://doi.org/b5m7r9.
Ballén-Vanegas MA, Galeano-Petro L, Guevara-Pardo G. Prevalence Of Braf, K-Ras, H-Ras, And N-Ras Mutations And Ret-Ptc In Colombian Patients With Papillary Carcinoma Of The Thyroid. Toronto; 2013 [cited 2019 May 6]. Available from: https://bit.ly/2YcGNNV.
Hewitt SM, Lewis FA, Cao Y, Conrad RC, Cronin M, Danenberg KD, et al. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2008;132(12):1929-35.
Licencia
Derechos de autor 2019 Revista de la Facultad de Medicina
Esta obra está bajo una licencia Creative Commons Reconocimiento 3.0 Unported.
-
